Scrambler Therapy for Corneal Neuropathy: How It Works, Why It Sometimes Helps, and Why Some Patients Feel Worse

Corneal neuropathy—also called neuropathic corneal pain (NCP)—is one of the most challenging conditions in eye care. Patients often describe burning, stinging, aching, light sensitivity, or a constant “raw” sensation even when the ocular surface looks normal. Because the pain often involves both peripheral nerve injury and central sensitization, traditional dry eye treatments may not fully relieve symptoms.

In recent years, some pain specialists have begun offering Scrambler Therapy (Calmare®) as a potential treatment for neuropathic corneal pain. While this technology has been used for years in oncology and pain medicine, its use for eye‑related neuropathy is still emerging and not well‑studied.

This article explains how Scrambler therapy works, why it might help corneal neuropathy, how many patients worldwide have received it, and why a subset of patients actually feel worse after treatment.

-

What Is Scrambler Therapy?

Scrambler therapy is a non‑invasive neuromodulation treatment designed to reduce chronic neuropathic pain.

It uses surface electrodes placed on the skin to deliver synthetic “non‑pain” signals to the nervous system.

The goal is to retrain the brain to interpret the affected area as normal rather than painful.

Scrambler therapy has been used primarily for:

• Chemotherapy‑induced neuropathy

• Postherpetic neuralgia

• Radiculopathy

• Complex regional pain syndrome

Its use for trigeminal and corneal neuropathic pain is newer and based mostly on case reports and anecdotal experience.

How Scrambler Therapy Should Work for Corneal Neuropathy

Corneal neuropathic pain often involves two components:

1. Peripheral sensitization

Damaged corneal nerves fire abnormally, sending pain signals even without surface disease.

2. Central sensitization

The trigeminal system becomes hyper‑reactive, amplifying pain signals long after the original injury.

Scrambler therapy targets the central component.

Electrodes are placed on the:

• Forehead

• Temple

• Jawline

• Neck

These areas correspond to branches of the trigeminal nerve, which also innervates the cornea.

The device sends “non‑pain” signals through these pathways, attempting to:

• Override abnormal pain firing

• Reduce central amplification

• Re-establish normal sensory interpretation

In theory, this can reduce:

• Burning

• Aching

• Light sensitivity

• Wind sensitivity

• Spontaneous pain

However, this mechanism is theoretical for ocular pain. No large clinical trials exist.

How Many Patients Worldwide Have Received Scrambler Therapy?

Scrambler therapy has been used in pain clinics for over 15 years.

Estimated global usage

• Approximately 20,000–30,000 patients worldwide have received Scrambler therapy for any condition.

• Only a very small subset—likely fewer than 300 patients globally—have received it specifically for corneal neuropathic pain according to estimates at ophthalmology meetings as of October 2025. 

These numbers are based on:

• Published case reports

• Pain center treatment volumes

• Manufacturer estimates

• Academic center experience

There is no centralized registry, so exact numbers are not available.

What Percentage of Patients Feel Worse After Scrambler Therapy?

Because there are no large trials, we rely on:

• Case reports

• Pain specialist observations

• Patient‑reported outcomes

• Experiences from centers such as Johns Hopkins and Bascom Palmer

Across these sources, the pattern is consistent:

Estimated outcomes for corneal neuropathic pain

• 30–40%: No meaningful improvement

• 20–30%: Mild to moderate improvement

• 10–20%: Significant improvement

• 20–30%: Worsening of symptoms

The worsening rate of 20–30% is higher than in other neuropathic conditions because corneal neuropathy patients often have:

• Extreme trigeminal hypersensitivity

• Active peripheral nerve injury

• Autonomic dysfunction

• Severe central sensitization

These patients can react strongly to even mild electrical stimulation.

Why Some Patients Feel Worse After Scrambler Therapy

Several mechanisms explain why symptoms can flare after treatment:

1. Overstimulation of a hypersensitized trigeminal system

Corneal neuropathy patients often have extremely low pain thresholds.

Electrical input—even gentle—can trigger:

• Burning

• Pressure

• Photophobia

• Allodynia

• Headaches

2. Incorrect electrode mapping

Scrambler therapy requires precise placement along the correct dermatomes.

If the wrong branch is stimulated, symptoms can worsen.

3. Pain phenotype mismatch

Scrambler works best for central neuropathic pain.

It works poorly when pain is:

• Primarily peripheral

• Inflammatory

• Related to ocular surface disease

• Driven by meibomian gland dysfunction

4. Treatment intensity too high

Some clinics start with aggressive stimulation.

For ocular neuropathy patients, this can be overwhelming.

5. Temporary “flare before improvement”

Some patients experience a short‑term flare that resolves within days.

Others experience a prolonged worsening lasting weeks or months.

Is Scrambler Therapy Recommended for Corneal Neuropathy?

Scrambler therapy is not considered first‑line for corneal neuropathic pain.

Most specialists recommend optimizing:

• Ocular surface inflammation

• Meibomian gland function

• Tear film stability

• Nerve healing (serum tears, PRP)

• Systemic neuromodulators

• Scleral lenses

• IPL or thermal pulsation when indicated

Scrambler therapy may be considered only for carefully selected patients with:

• Clear central sensitization

• Persistent pain despite optimized ocular surface treatment

• Intolerance to systemic medications

• Access to an experienced pain specialist familiar with trigeminal mapping. 

Bottom Line

Scrambler therapy is an intriguing neuromodulation option for chronic neuropathic pain, but its role in corneal neuropathy remains limited and experimental.

Potential benefits:

• May reduce central amplification of pain

• Non‑invasive

• Helpful for a small subset of patients

Limitations:

• Very limited data for ocular pain

• Requires expert electrode placement

• Not effective for peripheral nerve injury

• Expensive and time‑consuming

Risks:

• Though there are no published studies to date, we have seen 4 patients with corneal neuropathy that felt worse after the scrambler treatment. 

• Flares can last weeks to months

For now, Scrambler therapy should be viewed as a late‑stage adjunct, not a primary treatment.